HIFU in Prostate Cancer
-
StatusAccepting Candidates
-
Age18 Years - N/A
-
SexesMale
-
Healthy VolunteersNo
Objective
This study will investigate the efficacy of focal high intensity focused ultrasound (HIFU) in patients with localized radiorecurrent prostate cancer. This study will also investigate the change in participant quality of life after HIFU therapy as compared to before HIFU therapy.
Description
Focal therapy is increasingly popular due to its minimal side effect profile. Furthermore, HIFU has demonstrated favorable oncologic outcomes in well selected patients, including those with intermediate and high risk disease. In patients with radiorecurrent prostate cancer there remains a paucity of data on the value of focal therapy. Review of focal HIFU rather than whole gland HIFU is based on largely retrospective data and in an era where mpMRI and PSMA PET was not yet widely implemented thus not reflecting the current patient population seeking this care. In fact, and to the investigators' knowledge, only one study has prospectively evaluated focal HIFU therapy in radiorecurrent prostate cancer. Further evaluation into the value of focal HIFU in select men with localized radiorecurrent clinically significant prostate cancer is needed (clinically significant prostate cancer defined as GG2 or above. GG1 prostate cancer will not be considered clinically significant prostate cancer), both in terms of oncologic and functional outcomes as this patient population is increasing.
Details
Full study title | Salvage Focal Therapy via High Intensity Focused Ultrasound (HIFU) in radiorecurrent localized prostate cancer |
Protocol number | OCR45064 |
ClinicalTrials.gov ID | NCT06402357 |
Phase | Phase 2 |
Eligibility
Inclusion Criteria:
Males who are ≥ 18 years of age
Eastern Cooperative Oncology Group Performance Status of 0-3
A history of prostate cancer treated with radiation therapy or proton beam therapy +/* hormone therapy
MRI or prostate-specific membrane antigen (PSMA) PET region of interest (ROI)
Biopsy proven clinically significant prostate cancer (GG2 or above) recurrence within or ipsilateral to the ROI lesion (within 6 months of the MRI/PET).
Contralateral grade group 1 (GG1) prostate cancer disease to the ROI
PSMA PET negative for metastatic disease (within 3 months of the biopsy)
Subjects must not have more than one active malignancy at the time of enrollment (Subjects with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen [as determined by the treating physician and approved by the PI] may be included).
Written informed consent obtained from the subject and the subject agrees to comply with all the study-related procedures.
Exclusion Criteria:
Contraindication to high intensity focused ultrasound (latex allergy, absent rectum, prior rectal fistula or significant rectal surgery making insertion of transrectal probe non-feasible or dangerous.)
Hormone therapy within 6 months of the screening period (Hormone therapy includes oral (relugolix, abiraterone, enzalutamide, apalutamide, darolutamide, casodex) injections (firmagon, Lupron))
History of Inflammatory Bowel Disease actively treated in last 3 years
Evidence of ≥ cT3 recurrent disease on imaging
Bilateral clinically significant prostate cancer (≥GG2 bilaterally)
GG1 prostate cancer at relapse biopsy (this will not be considered clinically significant prostate cancer)
History of brachytherapy seeds still implanted or other fiduciary marker which is near (same quadrant) as a planned treatment zone
Large Calcification on CT or transrectal ultrasound which, as per the review of the surgeon, limits or hinders a quality high intensity focused ultrasound to the region of interest
History of Urethral strictures
No prior radiation therapy for prostate cancer
Subjects without a ROI on MRI or PET
Metastatic disease or locally advanced disease (defined by pelvic lymph node involvement or T4 disease) on PSMA PET
History of any other disease, metabolic dysfunction, clinical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of protocol therapy or that might affect the interpretation of the results of the study or that puts the subject at high risk for treatment complications, in the opinion of the treating physician.
Prisoners or subjects who are involuntarily incarcerated, or subjects who are compulsorily detained for treatment of either a psychiatric or physical illness.
Lead researcher
-
Tarik Benidir, MDSurgical Oncologist (Surgical Specialist - Cancer), Urologist
Participate in a study
Here are some general steps to consider when participating in a research study:
-
Step1
Contact the research team
Call or email the research team listed within the specific clinical trial or study to let them know that you're interested. A member of the research team, such as the researcher or study coordinator, will be available to tell you more about the study and to answer any questions or concerns you may have.
Primary contact
-
Step2
Get screened to confirm eligibility
You may be asked to take part in prescreening to make sure you are eligible for a study. The prescreening process ensures it is safe for you to participate. During the prescreening process, you will be asked some questions and you may also be asked to schedule tests or procedures to confirm your eligibility.
-
Step3
Provide your consent to participate
If you are eligible and want to join the clinical trial or study, a member of the research team will ask for your consent to participate. To give consent, you will be asked to read and sign a consent form for the study. This consent form explains the study's purpose, procedures, risks, benefits and provides other important information, such as the study team's contact information.
-
Step4
Participate
If you decide to participate in a clinical trial or study, the research team will keep you informed of the study requirements and what you will need to do to throughout the study. For some trials or studies, your health care provider may work with the research team to ensure there are no conflicts with other medications or treatments.